{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:15:23Z","timestamp":1785366923498,"version":"3.55.0"},"reference-count":67,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Targeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with \u201clegacy\u201d chemotherapeutic agents that largely rely on abolishing cell division. New therapies can augment the T-cell recognition of tumor antigens and effectively prevent tumor cells from their historically successful ability to evade immune recognition. These novel agents cause acute and chronic toxicities to a variety of organ systems (enteritis, pneumonitis, hypophysitis, and hepatitis), and this may masquerade as other chronic illnesses or paraneoplastic effects. As the perioperative footprint of cancer patients increases, it is essential that perioperative providers\u2014anesthesiologists, surgeons, nurse anesthetists, and inpatient hospital medicine providers\u2014be up to date on the physiologic mechanisms that underlie these new therapies as well as their acute and subacute toxicity profiles. Immunotherapy toxicity can significantly impact perioperative morbidity as well as influence perioperative management, such as prophylaxis for adrenal insufficiency, preoperative pulmonary assessment, and screening for thyroid dysfunction, among others.<\/jats:p>","DOI":"10.3390\/curroncol30080554","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:09:33Z","timestamp":1692180573000},"page":"7638-7653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications"],"prefix":"10.3390","volume":"30","author":[{"given":"Alessandro","family":"De Camilli","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fischer","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/hed.26601","article-title":"Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer","volume":"43","author":"Mays","year":"2021","journal-title":"Head Neck"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","article-title":"Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report","volume":"99","author":"Ikeuchi","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics","volume":"140","author":"Olenchock","year":"2019","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: A large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Goswami S, Aparicio A, Subudhi SK (2016). Immune Checkpoint Therapies in Prostate Cancer. Cancer J., 22, 117\u2013120.","DOI":"10.1097\/PPO.0000000000000176"},{"key":"ref_13","unstructured":"(2023, August 01). Data Presented at AACR Support Potential of Peregrine\u2019s PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer. Reuters. Archived from the Original on 2014-05-21. Available online: https:\/\/www.biospace.com\/article\/releases\/data-presented-at-american-association-for-cancer-research-support-potential-of-peregrine-pharmaceuticals-inc-s-ps-targeting-immunotherapy-bavituxim\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"Opdivo-Nivolumab Injection (2020, March 11). DailyMed. 17 December 2019, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2017.00121","article-title":"The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study","volume":"7","author":"Elias","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.14309\/01.ajg.0000857512.69949.fc","article-title":"S218 Prevalence and Outcomes of Immune Checkpoint Inhibitor (ICI) Associated Colitis: A Population-Based Cohort Study","volume":"117","author":"Tunio","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ccr3.3597","article-title":"Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer","volume":"9","author":"Omori","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.31558","article-title":"Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis","volume":"73","author":"Mahmud","year":"2021","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S-714","DOI":"10.1016\/S0016-5085(18)32506-X","article-title":"Mo1236\u2014Incidence of Acute Pancreatitis with the use of Immune Checkpoint Inhibitors (ICI) in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"154","author":"George","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jemermed.2018.08.009","article-title":"Acute Pancreatitis: Updates for Emergency Clinicians","volume":"55","author":"Waller","year":"2018","journal-title":"J. Emerg. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed Cell Death-1 Inhibitor\u2013Induced Type 1 Diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","first-page":"144","article-title":"Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes","volume":"16","author":"Banavasi","year":"2021","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.chest.2021.10.041","article-title":"Incidence of Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer","volume":"161","author":"Poulose","year":"2022","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated With Anti\u2013Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e000840","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"570233","DOI":"10.3389\/fonc.2020.570233","article-title":"Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated with Radiotherapy","volume":"10","author":"Blanco","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e004670","DOI":"10.1136\/jitc-2022-004670","article-title":"Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: A multi-institutional cohort study","volume":"10","author":"Tiu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.21037\/tlcr-21-634","article-title":"Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer","volume":"10","author":"Qiu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Ful-minant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","first-page":"101390","article-title":"Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review","volume":"33","author":"Vartanov","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/23993693211002216","article-title":"Cancer therapy-induced hyponatremia: A case-illustrated review","volume":"5","author":"Pelletier","year":"2021","journal-title":"J. Onco-Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e002220","DOI":"10.1136\/jitc-2020-002220","article-title":"Immune checkpoint inhibitor-related hypogonadism and infertility: A neglected issue in immuno-oncology","volume":"9","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"836859","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte\u2013Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/IJGM.S261433","article-title":"Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review","volume":"13","author":"Azar","year":"2020","journal-title":"Int. J. Gen. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering better chimeric antigen receptor T cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kyte, J.A. (2022). Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers. Cancers, 14.","DOI":"10.3390\/cancers14030571"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_54","unstructured":"Helwick, C. (2008). Novel BiTE antibody mediates contact between T cells and cancer cells. Oncol. NEWS Int., 17."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1182\/blood-2019-123757","article-title":"An individualized risk mitigation approach for safety: Experience from the mo-sunetuzumab (CD20\/CD3 bispecific antibody) development program in relation to neurotoxicity risk [abstract]","volume":"134","author":"Diefenbach","year":"2019","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_58","first-page":"705","article-title":"Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Ev-idence to Date","volume":"16","author":"Si","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1182\/blood-2022-169809","article-title":"Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11910-013-0383-y","article-title":"Septic Encephalopathy","volume":"13","author":"Ziaja","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 Car T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"18741","DOI":"10.18632\/aging.104058","article-title":"A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy","volume":"12","author":"Cai","year":"2020","journal-title":"Aging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/8\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:34:38Z","timestamp":1760128478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/8\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["curroncol30080554"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30080554","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]}}}